humanised dinutuximab (Hu14.18K322A) / Essential Pharma 
Welcome,         Profile    Billing    Logout  
 32 Diseases   1 Trial   1 Trial   58 News 
1 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
humanised dinutuximab (Hu14.18K322A) / Essential Pharma
NCT01857934: Therapy for Children With Advanced Stage Neuroblastoma

Active, not recruiting
2
153
US
cyclophosphamide, Cytoxan(R), topotecan, Hycamtin(R), hu14.18K322A, humanized anti-GD2 antibody, monoclonal antibody, dinutuximab, peripheral blood stem cell harvest, PBSCH, surgical resection, cisplatin, Platinol-AQ(R), etoposide, VP16, Vepesid(R), Etopophos(R), doxorubicin, Adriamycin(R), vincristine, Oncovin(R), busulfan, Busulfex(R), melphalan, L-phenylalanine mustard, Phenylalanine mustard, L-PAM, L-sarcolysin, Alkeran(R), peripheral blood stem cell transplantation, PBSCT, natural killer cell infusion, NK cell infusion, radiation therapy, GM-CSF, sargramostim, Leukine(R), granulocyte macrophage colony stimulating factor, G-CSF, Granulocyte colony stimulating factor, Neupogen(R), Filgrastim, mesna, Mesnex(R), levetiracetam, Keppra, interleukin-2, IL-2, aldesleukin, Proleukin(R), Isotretinoin, 13-cis retinoic acid, CliniMACS, Cell Selection System
St. Jude Children's Research Hospital, Cookies for Kids' Cancer, CURE Childhood Cancer, Inc.
Neuroblastoma
10/21
12/24

Download Options